Background
Akshaya J
Too sweet to be true? Prophylactic SGLT2 ...

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery
Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
Background
Pallavi Prasad
On the right TRACK? Rivaroxaban to prevent ...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial

complement

VALIANT: The Visual Abstract

The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.

Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.